tradingkey.logo

Daxor Corp

DXR
12.895USD
+0.515+4.16%
收盘 12/19, 16:00美东报价延迟15分钟
64.27M总市值
37.08市盈率 TTM

Daxor Corp

12.895
+0.515+4.16%

关于 Daxor Corp 公司

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Daxor Corp简介

公司代码DXR
公司名称Daxor Corp
上市日期Jul 25, 1983
CEOFeldschuh (Michael Richard)
员工数量- -
证券类型Ordinary Share
年结日Jul 25
公司地址Suite 7120
城市NEW YORK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编10118
电话12122440555
网址https://www.daxor.com/
公司代码DXR
上市日期Jul 25, 1983
CEOFeldschuh (Michael Richard)

Daxor Corp公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
212.69K
+1.50%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
35.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
17.05K
+38.62%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--
Mr. Bret Shapiro
Mr. Bret Shapiro
IR Contact Officer
IR Contact Officer
--
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
212.69K
+1.50%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
35.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
17.05K
+38.62%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月27日 周四
更新时间: 11月27日 周四
持股股东
股东类型
持股股东
持股股东
占比
Joseph Feldschuh UEO
51.22%
Feldschuh (Michael Richard)
4.27%
Feldschuh (Jonathan Adam)
1.08%
The Vanguard Group, Inc.
0.98%
Renaissance Technologies LLC
0.58%
其他
41.86%
持股股东
持股股东
占比
Joseph Feldschuh UEO
51.22%
Feldschuh (Michael Richard)
4.27%
Feldschuh (Jonathan Adam)
1.08%
The Vanguard Group, Inc.
0.98%
Renaissance Technologies LLC
0.58%
其他
41.86%
股东类型
持股股东
占比
Individual Investor
57.11%
Investment Advisor
1.08%
Hedge Fund
0.58%
Research Firm
0.06%
其他
41.17%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
14
102.17K
2.33%
--
2025Q3
14
102.17K
2.33%
+2.08K
2025Q2
15
100.09K
2.26%
+3.04K
2025Q1
15
97.05K
2.30%
-16.23K
2024Q4
15
106.77K
1.91%
+12.72K
2024Q3
14
94.05K
1.85%
+4.76K
2024Q2
13
89.28K
1.77%
+4.12K
2024Q1
13
85.17K
1.54%
+11.30K
2023Q4
13
73.17K
1.98%
-131.00
2023Q3
12
73.30K
2.02%
-1.71K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Joseph Feldschuh UEO
2.55M
51.22%
--
--
May 19, 2025
Feldschuh (Michael Richard)
212.69K
4.27%
+3.14K
+1.50%
May 19, 2025
Feldschuh (Jonathan Adam)
35.91K
0.72%
--
--
May 19, 2025
The Vanguard Group, Inc.
49.03K
0.98%
--
--
Jun 30, 2025
Renaissance Technologies LLC
28.02K
0.56%
-100.00
-0.36%
Jun 30, 2025
Michel (Robert J)
17.05K
0.34%
+4.75K
+38.62%
May 19, 2025
Morgan Stanley Smith Barney LLC
3.56K
0.07%
+3.47K
+3986.21%
Jun 30, 2025
Desrosiers (Caleb J.D.)
3.16K
0.06%
--
--
May 19, 2025
SBI Securities Co., Ltd.
3.13K
0.06%
--
--
Jun 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Daxor Corp的前五大股东是谁?

Daxor Corp 的前五大股东如下:
Joseph Feldschuh UEO持有股份:2.55M,占总股份比例:51.22%。
Feldschuh (Michael Richard)持有股份:212.69K,占总股份比例:4.27%。
Feldschuh (Jonathan Adam)持有股份:35.91K,占总股份比例:0.72%。
The Vanguard Group, Inc.持有股份:49.03K,占总股份比例:0.98%。
Renaissance Technologies LLC持有股份:28.02K,占总股份比例:0.56%。

Daxor Corp的前三大股东类型是什么?

Daxor Corp 的前三大股东类型分别是:
Joseph Feldschuh UEO
Feldschuh (Michael Richard)
Feldschuh (Jonathan Adam)

有多少机构持有Daxor Corp(DXR)的股份?

截至2025Q4,共有14家机构持有Daxor Corp的股份,合计持有的股份价值约为102.17K,占公司总股份的2.33%。与2025Q3相比,机构持股有所增加,增幅为--。

哪个业务部门对Daxor Corp的收入贡献最大?

在--,--业务部门对Daxor Corp的收入贡献最大,创收--,占总收入的--%。
KeyAI